Showing results (181-190 of 201) with videos related to
Sort By:
Pageof 21
Nature|October 26, 2022
Single-cell genomic variation induced by mutational processes in cancerTyler Funnell, Ciara H O'Flanagan, Marc J Williams, et al.Journal for Immunotherapy of Cancer|March 27, 2020
Consensus guidelines for the definition, detection and interpretation of immunogenic cell deathLorenzo Galluzzi, Ilio Vitale, Sarah Warren, et al.JCO Precision Oncology|January 29, 2026
Age-Related Germline Landscape of Endometrial Cancer: Focus on Early-Onset CasesJudy J Wang, Juliet Milani, Sarah Kane, et al.Gynecologic Oncology|March 16, 2024
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptakeMaureen Byrne, Tiffany Y Sia, Christopher Fong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.Cell|March 31, 2026
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapyZeda Zhang, Yu-Jui Ho, Xin Fang, et al.Gynecologic Oncology|August 14, 2025
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?Tiffany Y Sia, Sara Moufarrij, Juliet Milani, et al.Cancer|August 30, 2022
Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variantsYing L Liu, Anna Maio, Yelena Kemel, et al.Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary CancersJohnathan Amsalem, Irina Ostrovnaya, Andrew R Marderstein, et al.NPJ Precision Oncology|July 17, 2026
PTCH1 mutations and tumor-agnostic clinical outcomes with hedgehog pathway inhibitors across cancer typesAntoine Desilets, Matteo Repetto, Soo Ryum Yang, et al.Pageof 21